Prevalence of Drug-Resistant Tuberculosis in Mainland China: Systematic Review and Meta-Analysis by Yang, Yu et al.
Prevalence of Drug-Resistant Tuberculosis in Mainland
China: Systematic Review and Meta-Analysis
Yu Yang, Xiangwei Li, Feng Zhou, Qi Jin*, Lei Gao*
State Key Laboratory for Molecular Virology and Genetic Engineering, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical
College, Beijing, China
Abstract
Background: The spread of drug-resistant tuberculosis (TB) is one of the major public health problems in the world.
Surveillance of anti-TB drug resistance is important for monitoring TB control strategies. However, the status of drug-
resistant TB in China has been reported inconsistently.
Methods: We systematically reviewed published studies on drug-resistant TB in China until March 31, 2011, and
quantitatively summarized prevalence and patterns of anti-TB drug resistance among new cases and previously treated
cases, respectively.
Results: Ninety-five eligible articles, published during 1993–2011, were included in this review. The meta-analyses showed
that the prevalence of drug-resistant TB in new cases was 27.9% (95% CI, 25.6%–30.2%) (n/N=27360/104356) and in
previously treated cases was 60.3% (95% CI, 56.2%–64.2%) (n/N=30350/45858). Furthermore, in these two study
populations, the prevalence of multiple drug resistance was found to be 5.3% (95% CI, 4.4%–6.4%) (n/N=8810/101718) and
27.4% (95% CI, 24.1%–30.9%) (n/N=10486/44530) respectively. However, the results were found to be frequently
heterogeneous (p for Q tests ,0.001). The most common resistance was observed for isoniazid among both study
populations. Different patterns of drug resistance were observed in the subgroup analysis with respect to geographic areas,
drug susceptibility testing methods and subject enrollment time.
Conclusions: Results of meta-analyses indicated a severe status of drug-resistant TB in China, which attaches an importance
to strength TB prevention and control.
Citation: Yang Y, Li X, Zhou F, Jin Q, Gao L (2011) Prevalence of Drug-Resistant Tuberculosis in Mainland China: Systematic Review and Meta-Analysis. PLoS
ONE 6(6): e20343. doi:10.1371/journal.pone.0020343
Editor: Sebastien Gagneux, Swiss Tropical and Public Health Institute, Switzerland
Received January 29, 2011; Accepted April 20, 2011; Published June 3, 2011
Copyright:  2011 Yang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work was supported by Eleven Fifth Key Research grant from the Ministry of Science and Technology, the People’s Republic of China (NO:
2008ZX10003-005, 2008ZX10003-012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jinqi@ipbcams.ac.cn (QJ); gaolei@ipbcams.ac.cn (LG)
Introduction
The prevalence of anti-tuberculosis (TB) drug resistance, which
increases the rate of treatment failure and the costs of control, is a
major challenge to global public health [1–3]. Together with delayed
diagnosis and lack or inadequacy of TB control programs, the
emergence of multidrug-resistant (MDR) TB has complicated the
epidemiology of TB [4,5]. It is estimated that, at present, 5% of the
more than 9 million persons who develop TB around the world every
year are infected with MDR-TB. China rankssecond in terms of total
numbers of MDR-TB cases which is only inferior to India [2,6].
As reported, increased drug resistance rates to the first-line anti-
TB drugs and MDR were observed in China in the past decade
[7,8]. However, these estimates presented high degrees of
variability because the study setting were heterogeneous (i.e.
population involved, geographic areas, outcome measurements,
etc.). In 2000, the Fourth National Epidemiological Sampling
Survey of Tuberculosis estimated the prevalence of TB infection in
China is as high as 44.5%, and there were around 0.5 million
drug-resistant TB cases among 200 million smear positive
pulmonary TB patients [9]. Report of National Baseline Survey of
Drug-resistant Tuberculosis (2007–2008) showed that resistance to at
least one anti-TB drug (any resistance) among new cases with
smear positive pulmonary TB was 35.2% (resistance to only one
drug was 21.3% and to multidrug was 8.2%) and among
previously treated cases was 55.2% (resistance to only one drug
was 20.0% and to multidrug was 9.5%), respectively [10]. The
high prevalence of drug-resistant TB suggested that persistent
surveillance is essential and important to evaluate and improve the
strategies of disease prevention and control.
The present study will be a priority to consider the prevalence
and distribution of drug-resistant TB in mainland China using
meta-analysis based on systematic review of articles published
between February 1993 and March 2011. The relevant estimates
were evaluated for new cases and previously treated cases,
respectively, which will provide more detailed information to
clearly overview the status of drug-resistant TB in China.
Results
A total of 4511 articles were achieved by literature search
using different combination of key terms from the databases as
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20343shown in Figure 1. After exclusion based on title and abstract
evaluation, 240 articles were retrieved for detailed full-text
evaluation. Finally, 95 studies, 7 in English and 88 in Chinese,
addressing the prevalence of drug-resistant TB in new cases
or in previously treated cases were identified, and please
refer to Table S1 for more detailed information on study
identification.
As shown in Table S2, among the included articles, 85
provided information of new cases and 66 provided data of
previously treated cases. 94 studies provided detailed results of
Figure 1. Flow diagram of study identification.
doi:10.1371/journal.pone.0020343.g001
Drug-Resistant Tuberculosis in China
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e20343drug susceptibility testing (DST) with respect to specific drugs.
According to the methods of DST, 53, 33 and 9 studies used
absolute concentration method, the proportion method and
BACTEC, respectively. More studies were conducted in East
(38) and South (15) China as compare to North (18), Central (14)
and West (11) China.
Table 1 shows the meta-analyses of the status of TB drug
resistance in new cases in China. In total, 83 studies were included.
The summarized prevalence of any drug resistance, mono-drug
resistance and MDR were found to be 27.9% (25.6%–30.2%) (n/
N=27360/104356), 12.4% (11.1%–13.8%) (n/N=5797/46049)
and 5.3% (4.4%–6.4%) (n/N=8810/101718), respectively. How-
ever, evident heterogeneity was observed (p,0.001). Figure S1
shows forest plot of meta-analysis of any drug resistance. As shown
in Figure S2, no evident publication bias was observed (p=0.717
for Begg rank correlation analysis; p=0.380 for Egger weighted
regression analysis). In the stratified analyses, the prevalence of any
drug resistance was observed to be varied by geographic areas
(p,0.001) and DST methods (p,0.001). Lower rates were
observed for studies from East and South China, and studies
using the proportion method of DST. The end time of the cases
enrollment (before 2000 or after 2000) did not significantly change
the results (p=0.916).
As shown in Table 2, the status of TB drug resistance in
previously treated cases in China was evaluated by meta-analysis.
In total, 62 studies were included and their results were found to
be heterogeneous in the meta-analyses as well (p,0.001). The
summarized prevalence of any drug resistance, mono-drug
resistance and MDR in the study population were found to be
60.3% (56.2%–64.2%) (n/N=30350/45858), 15.6%(13.5%–
18.0%) (n/N=2462/15177) and 27.4% (24.1%–30.9%) (n/
N=10486/44530), respectively. Forest plot for the analysis of
any drug resistance was shown in Figure S3. Some evidence for
publication bias was observed (p=0.951 for Begg rank correlation
analysis; p=0.002 for Egger weighted regression analysis), and
please refer to Figure S4 for funnel plot. In the subgroup
analyses, the prevalence of any drug resistance was observed to be
influenced by geographic areas (p,0.001), DST methods
(p,0.001) and enrollment period (p,0.001). Lower rates were
observed for studies from East and South China, studies using the
proportion method of DST, and studies with the end time of
subject enrollment after 2000.
Table S3 shows the meta-analyses on patterns of TB drug
resistance in new cases in China. The most common drug
resistance was observed for isoniazid and streptomycin with a
summarized any prevalence of 15.3% (13.1%–17.7%) and 14.3%
(12.4%–16.5%) respectively. Among MDR, the most common
form of drug resistance was HRS with a prevalence of 2.0%
(1.5%–2.5%). Distribution of anti-TB drug resistance in previously
treated cases was estimated by means of meta-analysis as shown in
Table S4. Similarly, the most common resistance was observed
for isoniazid and rifampicin with a summarized combined
prevalence of 41.5% (36.6%–46.6%) and 34.6% (30.1%–39.4%)
respectively.
In additional sensitivity analyses, excluding studies with smaller
sample size, the prevalence of any drug resistance was not
substantially changed in new cases as 27.7% (25.0%–30.5%)
(p=0.603) but statistically increased in previously treated cases as
63.7% (59.1%–68.0%) (p,0.001).
Discussion
This review addressed the prevalence and distribution of drug-
resistant TB in mainland China. Ninety-five articles performed
DST among new cases or previously treated cases were identified
for meta-analysis. The results were found to be frequently
heterogeneous. Our analyses showed that the prevalence of
drug-resistant TB in new cases was 27.9% (25.6%–30.2%) (n/
N=27360/104356) and in previously treated cases was 60.3%
(56.2%–64.2%) (n/N=30350/45858). Furthermore, in these two
study populations, the prevalence of MDR was found to be 5.3%
(4.4%–6.4%) (n/N=8810/101718) and 27.4% (24.1%–30.9%)
(n/N=10486/44530), respectively. Different patterns of drug
resistance were observed with respect to geographic areas, study
period and methods of drug-susceptibility testing.
Streptomycin, the first anti-TB drug, was introduced in 1944
and showed impressive therapeutic outcomes [11]. However,
monotherapy was found to be ineffective to against TB because of
the easily appeared drug resistance. Combination therapy then
was developed and widely used which can reach better anti-TB
effect and largely reduce the rate of resistance to multiple drugs.
Thereafter, drug-resistant TB was recognized as a major problem
again since MDR-TB was reported in worldwide. Multiple
explanations have been suggested to contribute to the spread of
MDR-TB around the world, including lack or inadequacy of anti-
TB strategies, inadequate treatment programs, and insufficient
resources, as well as delayed diagnosis of TB [5,12]. In China, the
spread of drug-resistant TB draws attention since the Fourth
National Epidemiological Sampling Survey of Tuberculosis in
2000. Therefore, in 2002, Guideline on Enforcement of Chinese
Tuberculosis Control Program was published by the Department of
Disease Control of Ministry of Health [7,13]. This Guideline was
constituted to standardize programs for TB prevention and
treatment, health workers will directly observe all patients to help
improve TB case management and to enhance drug resistance
surveillance and control.
In our analyses, TB patients were divided into two subgroups:
new cases and previously treated cases. The prevalence of the drug
resistance among new cases will reflect the transmission status of
drug-resistant TB among general population. We found more than
a quarter of the newly diagnosed TB cases (27.9%) were resistant
to at least one drug and 5.3% of them were MDR. Such a high
prevalence is a big challenge to achieve more than 90% cure rates
[14–16]. The prevalence of the drug resistance among previously
treated cases might partly reflect the treatment efficacy. Drug
resistance was found might explain more than a half of re-
treatments (60.3%), which suggests previously treated cases should
be a major target population for drug resistance surveillance. Also,
standard treatment strategies and availability of second-line drugs
for drug-resistant TB should be paid attention to. In the other
hand, there was still a proportion of re-treatment was not related
to drug resistance, it indicates cases management should be
improved to minimize the drop-out and lost to follow up [17].
Stratified analyses were performed in the present study
according to the geographic areas, enrollment time and DST
methods. We found most of the included studies came from East
China and South China and relatively lower drug resistant rates
were reported by them. The better social-economic status might
contribute to such an observation because of the corresponding
higher medical and public health levels of these two areas.
Potential bias caused by the limited number of studies from areas
with lower social-economic status could not be excluded. To
minimize the gap between the areas is also an important project
to the health system [18]. We found DST methods also influence
the drug resistance rates. It might be explained by the different
sensitivity of the methods and reminds us to consider this
important issue when systematically reviewing the results of
different studies. In addition, a decline of drug resistance was
Drug-Resistant Tuberculosis in China
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Prevalence of Drug
Resistance
(95% CI) (%) n/N
No. of
Studies Heterogeneity Test
I
2(%) p
Any drug
resistance
Total 27.9 (25.6–30.2) 27360/104356 83 98.2 ,0.001
Stratified by geographic areas
North China 34.7(28.9–41.0) 12258/40676 17 98.8 ,0.001
East China 21.5(18.8–24.5) 6967/36337 36 97.3 ,0.001
South China 26.9(23.1–31.0) 3888/15968 11 96.0 ,0.001
Central China 36.4(30.2–43.1) 2751/7839 12 96.4 ,0.001
West China 30.3(22.9–38.8) 1786/5254 9 97.4 ,0.001
Stratified by years
Before (include) 2000 26.2(22.4–30.5) 6890/27874 36 97.8 ,0.001
After 2000 26.0(22.7–29.5) 9512/38426 38 98.1 ,0.001
Stratified by DST methods
Absolute concentration method 28.0(24.7–31.5) 15970/60180 45 98.3 ,0.001
The proportion method 26.7(23.4–30.2) 8965/32620 32 97.8 ,0.001
BACTEC 29.7(22.4–38.2) 1699/6709 7 97.6 ,0.001
Mono-drug
resistance
Total 12.4(11.1–13.8) 5797/46049 59 94.4 ,0.001
Stratified by geographic areas
North China 11.9(8.4–16.6) 1044/7152 8 96.5 ,0.001
East China 11.3(9.1–13.9) 1652/15440 23 95.0 ,0.001
South China 14.4(11.7–17.6) 2065/15968 11 95.3 ,0.001
Central China 13.1(10.2–16.6) 472/3637 10 85.6 ,0.001
West China 13.1(9.5–17.9) 380/2923 6 92.7 ,0.001
Stratified by years
Before (include) 2000 10.9(9.6–12.5) 2535/24073 31 91.3 ,0.001
After 2000 12.8(10.5–15.4) 1934/14521 21 94.7 ,0.001
Stratified by DST methods
Absolute concentration method 11.8(9.7–14.2) 1759/15607 28 94.2 ,0.001
The proportion method 13.4(11.6–15.3) 3351/23995 24 94.0 ,0.001
BACTEC 11.8(7.9–17.3) 687/6447 6 96.5 ,0.001
Multi-drug
resistance
Total 5.3(4.4–6.4) 8810/101718 76 98.2 ,0.001
Stratified by geographic areas
North China 6.6(4.5–9.5) 5582/38413 14 98.4 ,0.001
East China 3.8(3.1–4.6) 1244/35307 33 90.8 ,0.001
South China 4.8(3.6–6.4) 818/15968 11 92.8 ,0.001
Central China 10.1(7.2–14.2) 704/7725 11 95.0 ,0.001
West China 7.3(5.1–10.3) 556/6493 9 93.0 ,0.001
Stratified by years
Before (include) 2000 4.8(3.7–6.1) 1485/27969 35 95.4 ,0.001
After 2000 5.3(4.4–6.4) 2020/37354 35 94.3 ,0.001
Stratified by DST methods
Absolute concentration method 4.4(3.2–6.0) 5955/56026 38 98.2 ,0.001
The proportion method 6.1 (4.6–7.9) 2265/34136 32 97.4 ,0.001
BACTEC 7.4(5.2–10.3) 494/6709 7 92.5 ,0.001
Abbreviation: BACTEC, use of BACTEC 460 TB system in tuberculosis diagnosis; DST, drug-susceptibility testing; n, number of events(drug resistance); N, total number of
patients from the included studies.
doi:10.1371/journal.pone.0020343.t001
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to the end of enrollment time. It is imagined that standard
surveillance and treatment programs applied after 2000 might
played a role in reducing drug resistance. Due to more detailed
data on specific time point could not be obtained from the
included studies, it is difficult to compare our analyses with the
Table 2. Status of drug-resistant tuberculosis among previously treated cases in China.
Prevalence of Drug
Resistance
(95% CI) (%) n/N
No. of
Studies Heterogeneity Test
I
2(%) p
Any drug resistance Total 60.3 (56.2–64.2) 30350/45858 62 98.2 ,0.001
Stratified by geographic areas
North China 67.8(60.7–74.2) 18184/25463 14 98.4 ,0.001
East China 58.8(52.0–65.3) 9022/14362 27 98.2 ,0.001
South China 55.2(43.0–61.4) 1537/3023 9 95.8 ,0.001
Central China 61.1(52.6–69.1) 1575/2781 9 94.6 ,0.001
West China 66.3(47.5–81.1) 1848/2667 5 97.1 ,0.001
Stratified by years
Before (include) 2000 61.5(53.1–69.3) 5303/8537 21 97.8 ,0.001
After 2000 56.1(49.8–62.3) 6559/11856 33 97.5 ,0.001
Stratified by DST methods
Absolute concentration method 66.7(62.5–70.7) 23557/32794 29 97.3 ,0.001
The proportion method 53.2(49.2–57.2) 5755/10478 29 93.0 ,0.001
BACTEC 71.6(52.6–85.2) 2469/3644 5 98.9 ,0.001
Mono-drug resistance Total 15.6(13.5–18.0) 2462/15177 39 92.7 ,0.001
Stratified by geographic areas
North China 25.2(14.2–40.6) 916/5028 8 98.4 ,0.001
East China 14.6(12.1–17.6) 501/3346 15 79.8 ,0.001
South China 16.7(15.2–18.4) 475/2857 8 25.3 0.226
Central China 12.8(10.2–15.9) 206/1605 6 63.4 0.018
West China 11.6(6.7–19.4) 364/2341 3 83.1 0.003
Stratified by years
Before (include) 2000 14.6(12.5–17.0) 660/4474 15 74.4 ,0.001
After 2000 14.2(12.4–16.3) 643/4386 16 68.9 ,0.001
Stratified by DST methods
Absolute concentration method 16.0(12.4–20.6) 642/3915 17 92.0 ,0.001
The proportion method 16.3(12.5–21.5) 1236/7618 18 95.7 ,0.001
BACTEC 15.8(13.6–18.3) 584/3644 5 63.9 0.026
Multi-drug resistance Total 27.4(24.1–30.9) 10486/44530 57 97.9 ,0.001
Stratified by geographic areas
North China 25.9(20.3–32.4) 4760/24648 11 98.2 ,0.001
East China 26.4(21.4–32.1) 3274/13448 25 97.4 ,0.001
South China 21.5(16.2–27.9) 672/3023 9 93.1 ,0.001
Central China 29.2(24.7–34.1) 798/2660 8 85.4 ,0.001
West China 38.2(23.8–55.0) 1380/3189 6 97.9 ,0.001
Stratified by years
Before (include) 2000 25.9(20.7–31.9) 2097/8403 20 96.6 ,0.001
After 2000 25.2(20.8–30.3) 2955/11462 30 96.8 ,0.001
Stratified by DST methods
Absolute concentration method 24.7(21.0–28.9) 6055/31058 24 97.4 ,0.001
The proportion method 27.7(23.6–32.2) 3290/10886 29 95.5 ,0.001
BACTEC 39.8(27.2–53.9) 1405/3644 5 98.0 ,0.001
Abbreviation: BACTEC, BACTEC 460 TB system of anti-tubercular screening; DST, drug-susceptibility testing; n, number of events(drug resistance); N, total number of
patients from the included studies.
doi:10.1371/journal.pone.0020343.t002
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However, an important point should be noticed that the
prevalence of MDR was as low as 9.5% among previously
treated cases as reported by the national survey. But it is much
higher in our meta-analyses performed among all included
studies (27.4%) and studies enrolled subjects after 2000 (25.2%).
The characteristics of the studied previously treated cases, like
the proportions of treatment failure cases and treatment
discontinued cases, might be one of the major factors contribute
to such an inconsistency. Our sensitivity analyses also indicated
the result of previously treated cases was much sensitive as
compared to the estimate of new cases. Therefore, the status of
drug-resistant TB among previously treated cases should be
assessed in more detail according to the characteristics of study
population in the future studies.
Some limitations of this systematic review should be considered
for results interpretation. First, the potential influence of age, sex,
ethnicity, economic level and life styles could not be analyzed due
to the limited information obtained from the original articles.
Second, potential publication bias cannot be completely excluded
as pronounced results are more likely to be published, especially
indication of some publication bias was observed in our analyses.
Third, most included studies were hospital-based rather than
population-based which makes the results more prone to potential
selection bias. Fourth, potential language bias could not be
excluded completely because our literature search only considered
articles published in English and in Chinese. Fifth, evident
heterogeneity observed in included studies should be kept in mind
when interpret our results [19]. As suggested by our subgroup
analyses, it might be explained, at least in part, by various study
populations and study design (e.g. study period and DST
methods).
In conclusion, this systematic review summarized the prevalence
and distribution of drug-resistant TB among new cases and
previously treated cases in mainland China. Our results suggested
that effective strategies to minimize the acquired drug resistance,
to control the transmission of resistance, to improve the diagnosis
measures should be attached importance for TB control in China.
Materials and Methods
Literature identification
Studies addressing drug resistance of TB in mainland China,
published in English or Chinese, were identified by searching for
original articles in several electronic databases until 31 March
2011. Chinese BioMedical Literature Database (1978-), PubMed
(1946-), MEDLINE (1947-), EMBASE (1974-) and the Cochrane
CENTRAL database (1972-). Combinations of the key words
‘‘tuberculosis’’, ‘‘drug resistance’’ and ‘‘China’’ were used to
screen for potentially relevant studies. Additional studies were also
indentified by cross-referencing.
Inclusion and Exclusion criteria
Original articles presented cross-sectional or cohort studies and
reported the prevalence of drug resistance of TB in mainland
China were considered. The included studies should provide drug
resistance data of either new cases or previously treated cases, or
both. If the study was reported in duplicate, the version firstly
published or published in English was included. Review articles,
congress abstracts, studies reported in languages other than
English or Chinese, data from the regions of China other than
mainland (i.e. TaiWan, HongKong and Macao), and studies using
non-standard study methods and definition were excluded. In
order to minimize the potential bias caused by too small sample
size, articles with less than 100 subjects in the subgroup of new
cases and previously treated cases were excluded.
Data extraction
For all studies, we extracted the following data from the original
publications: first author and year of publication, study enroll time
and population, distribution of age and sex in the study
population, DST methods, prevalence of mono- and multi-drug
resistance and any drug resistance. Data on most widely used first-
line anti-TB drugs (i.e. H, isoniazid; R, rifampin; E,ethambutol;
and S, streptomycin) were extracted as well. Different patterns of
multi-drug resistance were accordingly indicated by HR, HRS,
HRE and HRSE. DST methods include absolute concentration
method, the proportion method and BACTEC method. The term
‘‘BACTEC’’ refer to use of BACTEC 460 TB system in the
diagnosis of tuberculosis. The end time of subject enrollment was
classified into before (include) 2000 and after 2000 considering the
launch of ‘‘TB Treatment and Control Planning of China (2001–
2010)’’ which strengthened TB prevention and control in county-
wide. Literature identification and data extraction was performed
by two researchers independently. The discrepancies between the
reviewers in either the decision on inclusion or exclusion of studies
or on data extraction were discussed by the study team to make the
final decision.
In the text, the term ‘‘resistance among new cases’’ refers to
patients with pulmonary TB who have never received anti-TB
drugs or have received less than one month of treatment. The term
‘‘resistance among previously treated cases’’ is used to refer to
patients who had previously received anti-TB drugs for one month
or more. ‘‘Mono resistance’’ was used to define the resistance to
only one first-line anti-TB drug. ‘‘Multi-drug resistance’’ (MDR)
was used to define the resistance to at least isoniazid and rifampin.
‘‘Any drug resistance’’ referred to resistance to any drug regardless
of mono-resistance or MDR.
Statistical analysis
Meta-analyses were carried out using Comprehensive Meta-
Analysis (V2.0, Biostat, Englewood, NJ, USA) for the prevalence
of drug-resistant TB among new cases and previously treated
cases, respectively [20]. Stratified analyses were subsequently
performed with respect to the geographic areas, the end time of
the enrollment period and DST methods (absolute concentration
method, the proportion method and BACTEC 460 TB system).
Random effects models were used, taking into account the
possibility of heterogeneity between studies, which was tested
with the Q test and I
2 test. Begg rank correlation and Egger
weighted regression methods were used to statistically assess
publication bias (p,0.05 was considered indicative of statistically
significant publication bias). Differences of the results in the
subgroup analyses were assessed by chi-square tests. Sensitivity
analyses were performed after excluding those studies with
sample size less than 200 for both new cases and previously treat
cases.
Supporting Information
Figure S1 Forest plot of the meta-analysis on any drug
resistance in new cases. (‘‘*’’ in the figure means studies
reported by the same publication).
(TIF)
Figure S2 Funnel plot of the meta-analysis on any drug
resistance in new cases.
(TIF)
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resistance in previously treated cases. (‘‘*’’ in the figure
means studies reported by the same publication).
(TIF)
Figure S4 Funnel plot of the meta-analysis on any drug
resistance in previously treated cases.
(TIF)
Table S1 Included and excluded articles after full-text
evaluation.
(DOC)
Table S2 Detailed information of the included studies.
(XLS)
Table S3 Distribution of different patterns of TB drug
resistance among new cases in China.
(DOC)
Table S4 Distribution of different patterns of TB drug
resistance among previously treated cases in China.
(DOC)
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